Sionna Therapeutics, Inc. SION 深 沪
已收盘 10-31 16:00:00 美东时间
38.21
+0.200
+0.53%
华盛通- 最 高39.2599
- 今 开37.55
- 成交量 13.56万股
- 最 低 37.55
- 昨 收 38.01
- 总市值 16.87亿
- 52周最高 43.195
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 7.255
- 委 比 72.53%
- 总股本 4413.98万
- 历史最高 43.195
- 量 比 0.55
- 振 幅 4.50%
- 历史最低 7.255
- 每 手 1
- 风险率 7.10%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Metsera Receives Unsolicited Proposal from Novo Nordisk
Metsera Declares Novo Nordisk Proposal "Superior" Novo Nordisk Proposal Values Metsera at up to $77.75 per Share, a Total of Approximately $9 Billion Pursuant to Pfizer Merger Agreement, Met...
10-30 19:07
Lilly to Acquire Adverum Biotechnologies
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose Acquisition ali...
10-24 20:30
Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference
Sionna Therapeutics announced data at the 2025 North American Cystic Fibrosis Conference showing that its first-in-class NBD1 stabilizers, SION-719 and SION-451, were generally well-tolerated in Phase 1 trials and exceeded pharmacokinetic targets. New preclinical data revealed that these stabilizers restored the half-life of the F508del-CFTR protein to wild-type levels, potentially offering a significant advancement in CF treatment. The company i...
10-24 17:15
Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH J...
10-22 19:00
美股牛股 | 散户追捧+业务规模扩大！BYND大涨146.3%；生物技术股RANI涨26.7%
散户追捧+业务规模扩大！BYND大涨146.3%，近三交易日涨约6倍；生物技术股RANI涨26.7%，与中外制药达成重大合作协议>>
10-22 14:01
Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis
<p><p align="center"><em>SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis</em></p> <p align="center"><em>Topline data expected in mid-2026</em></p> <p>Sionna Therapeutics initiated the PreciSION CF Phase 2a trial to evaluate SION-719, a first-in-class NBD1 stabilizer, when added to Trikafta, the current standard of care for cystic fibrosis (CF). The trial aims to assess the safety, tolerability, pharmaco...
10-21 11:00
美股大行评级 | 潜在最高涨幅37.45%，甲骨文获多家机构上调目标价；瑞穗上调美光科技目标价升至240美元
今日重点评级关注：韦德布什：维持Artiva Biotherapeutics"跑赢大市"评级，目标价从18美元升至23美元；巴克莱：维持Cellectis"超配"评级，目标价从4美元升至8美元
10-20 10:03
Guardant Health To Present New Data From Across Its Oncology Portfolio In 15 Accepted Abstracts At The European Society For Medical Oncology Congress 2025, Taking Place October 17–21 In Berlin, Germany; Presentations Highlight The Power Of Guardant Health's Blood-Based Assays To Reduce Treatment Burden And Improve Disease Monitoring Across Multiple Cancer Types
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that new data from across its oncology portfolio will be presented in 15 accepted abstracts at the European Society for Medical
10-16 05:01
Lennar Launches Exchange Offer of Millrose Stock for Lennar Stock
MIAMI, Oct. 10, 2025 /PRNewswire/ -- Lennar Corporation (NYSE: LEN and LEN.B) ("Lennar"), one of the nation's leading homebuilders, announced today its offer to exchange the approximately 20...
10-10 19:00
Robo.ai Inc. to Hold Extraordinary General Meeting on October 23, 2025
DUBAI, UAE, Oct. 8, 2025 /PRNewswire/ -- Robo.ai Inc. (Nasdaq: AIIO) (the "Company") today announced that it will hold an extraordinary general meeting of shareholders (the "EGM") at Office ...
10-08 18:30
